RNS Number : 96070 EKF Diagnostics Holdings PLC 13 August 2014

EKF Diagnostics Holdings plc ("EKF", the "Company")

Notice of results and investor briefing

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, will be reporting its interim results for the six months ended 30 June 2014 on Monday 15 September 2014.

Analyst briefing

Julian Baines (CEO) and Paul Foulger (FD) will be hosting a briefing for analysts on Monday 15 September 2014 at 10.00am at the London Capital Club, 15 Abchurch Lane, EC4N 7BW.

Investor briefing

The management team will also be presenting the Company's financial and operational results for investors on the evening of Wednesday 17 September 2014. The event is open to all investors and will be held at Rocket, 6, Adam's Court, Old Broad Street, EC2N 1DX, from 16:30 for a 16:45 start.

To register to attend the analyst briefing or investor briefing, please contact Walbrook PR (details below).

Enquiries:

Walbrook PR Limited Paul McManus Lianne Cawthorne **Tel: 020 7933 8780** or <u>ekf@walbrookpr.com</u> Mob: 07980 541 893 Mob: 07584 391 303

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection. The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market. In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

This information is provided by RNS The company news service from the London Stock Exchange

END

MSCEAKPAFALLEFF admin Notice of results and investor briefing 21956311 A Wed, 08/13/2014 - 07:00 Company Announcement - General EKF